Fluidigm to Present at Upcoming Investor Conferences
May 14 2021 - 8:30AM
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, announced today that the company’s management will
participate in several upcoming investor conferences and provide
updates on the company’s business strategy and growth plans.
- UBS Global Healthcare Virtual
ConferenceTuesday, May 25, 2021Fireside chat presentation
at 2:00 p.m. ET
- Oppenheimer MedTech, Tools & Diagnostics
SummitWednesday, May 26, 2021Pre-recorded presentation
made available the day of the conference
- Jefferies Virtual Healthcare
ConferenceWednesday, June 2, 2021Fireside chat
presentation at 3:00 p.m. ET
Webcasts of the live presentations can be accessed via the
investor relations section of the Fluidigm® website at Events
& Presentations. For those unable to participate in the live
events, the webcasts will also be archived on the Fluidigm Investor
Relations page at investors.fluidigm.com.
About Fluidigm Fluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF® and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, plant and animal research, and
clinical laboratories worldwide. Together with them, we strive to
increase the quality of life for all. For more information,
visit fluidigm.com.Fluidigm, the Fluidigm logo,
Advanta, and CyTOF are trademarks and/or registered trademarks
of Fluidigm Corporation in the United
States and/or other countries. All other trademarks are
the sole property of their respective owners. The Advanta™ Dx
SARS-CoV-2 RT-PCR Assay is for In Vitro Diagnostic Use. It is for
Use under Emergency Use Authorization Only. Rx Only. Other
Fluidigm products are provided for Research Use Only. Not for
use in diagnostic procedures.
Available InformationWe use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Contacts:Investors:Peter DeNardo415 389 6400ir@fluidigm.com
Media:Mark SpearmanSenior Director, Corporate Communications650
243 6621mark.spearman@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Apr 2023 to Apr 2024